Global Oligonucleotide Therapeutics Market to Reach $4.4 Billion by 2030
The global market for Oligonucleotide Therapeutics estimated at US$2.3 Billion in the year 2022, is projected to reach a revised size of US$4.4 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2022-2030. Antisense / RNAI Oligonucleotides, one of the segments analyzed in the report, is projected to record 9.4% CAGR and reach US$3.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Other Technologies segment is readjusted to a revised 6.4% CAGR for the next 8-year period.
The U.S. Market is Estimated at $689.1 Million, While China is Forecast to Grow at 7.9% CAGR
The Oligonucleotide Therapeutics market in the U.S. is estimated at US$689.1 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$744.9 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7% CAGR.Select Competitors (Total 44 Featured) -
- Arrowhead Pharmaceuticals, Inc.
- GlaxoSmithKline PLC
- Ionis Pharmaceuticals, Inc.
- miRagen Therapeutics, Inc.
- Sarepta Therapeutics Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Oligonucleotide Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 3: World 16-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 6: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 9: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 12: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 13: World Oligonucleotide Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- Table 14: World Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 15: World Historic Review for Oligonucleotide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 16: World 16-Year Perspective for Oligonucleotide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Antisense / RNAI Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 18: World Historic Review for Antisense / RNAI Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 19: World 16-Year Perspective for Antisense / RNAI Oligonucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 20: USA Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 21: USA Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 22: USA 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
- Table 23: USA Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 24: USA Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 25: USA 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
- CANADA
- Table 26: Canada Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 27: Canada Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 28: Canada 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
- Table 29: Canada Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 30: Canada Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 31: Canada 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
- JAPAN
- Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 32: Japan Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 33: Japan Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 34: Japan 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
- Table 35: Japan Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 36: Japan Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 37: Japan 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
- CHINA
- Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 38: China Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 39: China Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 40: China 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
- Table 41: China Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 42: China Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 43: China 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
- EUROPE
- Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 44: Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 45: Europe Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 46: Europe 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
- Table 47: Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 48: Europe Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 49: Europe 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
- Table 50: Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 51: Europe Historic Review for Oligonucleotide Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 52: Europe 16-Year Perspective for Oligonucleotide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- FRANCE
- Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 53: France Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 54: France Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 55: France 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
- Table 56: France Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 57: France Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 58: France 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
- GERMANY
- Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 59: Germany Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 60: Germany Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 61: Germany 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
- Table 62: Germany Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 63: Germany Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 64: Germany 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
- ITALY
- Table 65: Italy Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 66: Italy Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 67: Italy 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
- Table 68: Italy Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 69: Italy Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 70: Italy 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
- UNITED KINGDOM
- Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 71: UK Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 72: UK Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 73: UK 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
- Table 74: UK Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 75: UK Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 76: UK 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
- REST OF EUROPE
- Table 77: Rest of Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 78: Rest of Europe Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 79: Rest of Europe 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
- Table 80: Rest of Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 81: Rest of Europe Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 82: Rest of Europe 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
- ASIA-PACIFIC
- Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 83: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 84: Asia-Pacific Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 85: Asia-Pacific 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
- Table 86: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 87: Asia-Pacific Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 88: Asia-Pacific 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
- REST OF WORLD
- Table 89: Rest of World Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 90: Rest of World Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 91: Rest of World 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2023 & 2030
- Table 92: Rest of World Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 93: Rest of World Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 94: Rest of World 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2023 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Arrowhead Pharmaceuticals, Inc.
- GlaxoSmithKline PLC
- Ionis Pharmaceuticals, Inc.
- miRagen Therapeutics, Inc.
- Sarepta Therapeutics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 193 |
| Published | April 2024 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 2.3 Billion |
| Forecasted Market Value ( USD | $ 4.4 Billion |
| Compound Annual Growth Rate | 8.4% |
| Regions Covered | Global |
